A tale of two halves - 2017
2017 has been an interesting year for Celgene as a whole. What began in 2017 as a strong bull-run for the stock of nearly 28% since February was quickly doused by a string of bad news and guidance decreases. Celgene represents one of a few number of companies that offers extremely long-term guidance. At its most recent 3Q earnings report, the company cut this long-term guidance, and it was followed by a nearly 20% tradedown in the stock following this.


